|
|||||
|
|
FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia |
|
| Authors: | Douglas D Fang Hengrui Zhu Qiuqiong Tang Guangfeng Wang Ping Min Qixin Wang Na Li Dajun Yang Yifan Zhai |
| Institution: | aAscentage Pharma (Suzhou) Co, Ltd, 218 Xinghu Street, Suzhou, Jiangsu Province, China;bState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China |
| Abstract: | |
| Keywords: | FLT3-ITD BCL-2 HQP1351 APG-2575 Acute myeloid leukemia |